Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Euraxi Pharma | INDUSTRY |
Not provided
Not provided
Not provided
Not provided
The purpose of this study is to evaluate the efficacy of fundoplication with stomach excluded in the suppression of disabling gastroesophageal reflux requiring surgery in patients who have undergone one anastomosis gastric bypass, with complete objective evaluation of reflux.
The FEE& RGOIC trial is a single-center, ambispective, interventional, non-randomized pilot study to evaluate the efficacy of Fundoplicature with stomach excluded objectively and comprehensively in the treatment of disabling gastroesophageal reflux requiring gastric bypass after anastomosis.
The strategy under study is objective reflux suppression after fundoplication with the stomach excluded in the following specific context: treatment of disabling gastroesophageal reflux requiring post-bypass surgery in Omega.
The eligible study population will be any adult patient at the investigating center who has undergone one-anastomosis gastric bypass surgery followed by fundoplication of the excluded stomach as part of treatment for disabling post-bypass gastro-oesophageal reflux, resistant to medical treatment and requiring surgery.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Gastroesophageal reflux disease | Experimental | Disabling post-bypass gastroesophageal reflux, resistant to medical treatment and requiring surgery |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Bypass surgery type one anastomosis gastric bypass | Procedure | Adult patients who have undergone single-anastomosis gastric bypass followed by fundoplication of the excluded stomach for the treatment of disabling post-bypass gastroesophageal reflux, resistant to medical treatment and requiring surgical intervention. |
| Measure | Description | Time Frame |
|---|---|---|
| Response rate after Fundoplicature with stomach excluded | The primary endpoint is the long-term efficacy of Fundoplicature with stomach excluded in the treatment of disabling Gastroesophageal Reflux Disease requiring Omega post-bypass surgery after surgery. | 2 years |
Not provided
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Arnaud LIAGRE, MD | Contact | 0562132758 | + 33 | arnaud.liagre@orange.fr |
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Clinique des Cèdres | Recruiting | Cornebarrieu | 31700 | France |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This is a pilot study that aims to objectively assess the resolution of gastroesophageal reflux following fundoplication with gastric exclusion in the following specific context: the treatment of debilitating gastroesophageal reflux requiring post-Omega bypass surgery.
This is not a comparative study of treatment arms. However, the study aims to compare data from pre- and post-operative examinations in order to observe the effect of the procedure on the objective assessment of gastroesophageal reflux symptoms.
Not provided
Not provided
Single-center, ambispective, interventional, non-randomized pilot study
Not provided
|